Presentation Transcript

1. Neurotransmitters In the 60's, people took acid to make the world weird. Now the world is weird and people take Prozac to make it normal.

2. Processes Involved in Neurotransmission • Precursors (getting the raw materials) • Biosynthesis (making the NTs) • Storage (vesicles - Golgi bodies) • Transport (neurofilaments and microtubules) • Docking • Influx of Ca++ • Vesiclemovement • Exocytosis— (fusion and release) • Crossing synaptic gap • Binding postsynaptic receptors • Reuptake mechanisms to recover NTs • Deactivation

4. Categories of NTs • Amino Acids • Glutamate (Glu) • GABA • Biogenic Amines • Quaternary Amines • Acetylcholine (Ach) • Monoamines • Catecholamines • Dopamine (DA) • Norepinephrine (NE) • Indolamines • Serotonin (5-HT) • Neuropeptides • Opioid Peptides • Enkephalins • Endorphins • Dynorphins • Others (e.g. lipids, nucleosides)

5. Receptors • Genetically-coded proteins embedded in cell membrane • Gating • Ligand-gated - Stretch-gated • Voltage-gated • Effects • Ionotropic • Metabotropic • Location • Postsynaptic • Presynaptic • Heteroreceptor • Autoreceptor ionotropic metabotropic

6. Ionotropic Receptors Work very fast; important role in fast neurotransmission Each is made of several subunits (together form the complete receptor) At center of receptors is channel or pore to allow flow of neurotransmitter At rest - receptor channels is closed When neurotransmitter bind -- channel immediately opens When ligand leaves binding site -- channel quickly closes

7. Metabotropic Receptors Work more slowly than ionotropic receptors Though it takes longer for postsynapic cell to respond, response is somewhat longer-lasting Comprise a single protein subunit, winding back-and-forth through cell membrane seven times (transmembrane domains) They do not possess a channel or pore

9. Theory of Drug Action Emil Fischer’s ‘Lock and Key’ Hypothesis (1890) • Every ‘lock’ has its own ‘key’ • If the ‘key’ is not precise, the ‘lock’ does not open • The ‘drug’ is the key that has to fit the target specifically and productively

10. Theory of Drug Action Corollary of ‘Lock & Key’ Hypothesis • Does not explain why some ‘keys’ open doors partially? …… e.g., partial agonists or antagonists

11. Theory of Drug Action Daniel Koshland’s ‘Induced-Fit’ Hypothesis (1958) • At least two steps …… step 1 is initial binding and step 2 is a change in structure of the receptor (and/or drug) • Receptor is flexible! …… can wrap around the drug

12. Common Neurotransmitters Involved in Dependence Probable functional dysregulation: • Dopamine (DA) • Serotonin (SER) • Acetylcholine (ACh) • Endorphins (END) • Gamma-aminobutyric acid (GABA) • Glutamate (GLU)

13. Drugs Associated with Neurotransmitters Why do people have “drugs of choice”? • Dopamine - amphetamines, cocaine, ETOH • Serotonin - LSD, ETOH • Endorphins - opioids, ETOH • GABA - benzodiazepines, ETOH • Glutamate –ETOH • Acetylcholine - nicotine, ETOH • Anandamide – Marijuana

14. Amino Acid NTs • High concentration in brain (micromolar) • Circuits • Cortico-cortical • Sensory-motor • Point-to-point communication • Consistently excitatory or inhibitory • Mainly ionotropic receptors but do have metabotropic receptors • Fast acting, short duration (1-5 ms) • Examples: Glutamate, Aspartate, GABA, Glycine

15. GABA and Glutamate . • Because they are structurally very similar, various drugs affect the presence of GLU and GABA in the synaptic gap and increase or decrease action potentials.

16. Ionotropic Glutamate • Principal excitatory NT • Biosynthesized as byproduct of cell metabolism • Removed by reuptake • Elevated levels  neurotoxic • 4 receptor types • NMDA • AMPA • Kainate • mGluR - Metabotropic

17. NMDA Binding Sites “The specific subunit composition of each receptor determines its overall pharmacological properties” • 4 outside cell • Glutamate • Glycine • Obligatory co-agonist • Inhibitory NT at its “own” receptor • Zinc (inverse agonist) • Polyamine (indirect agonist) • 2 inside cell • Magnesium (inverse agonist) • PCP (inverse agonist)

18. Glu GABA Glutamic Acid Decarboxylase (GAD) and B6 GABA (Gamma Aminobutyric Acid) • Principal Inhibitory NT • Biosynthesis: • Removed by reuptake • 2 receptor types • GABAA GABAC (ionotropic; Cl- channel) • GABAB(metabotropic; K+ channel)

19. GABAa Binding Sites • GABA • Benzodiazepine (indirect agonist) • Probably also site for alcohol • Endogenous inverse agonist binds here • Barbiturate (indirect agonist) • Steroid (indirect agonist) • Picrotoxin (inverse agonist) Phosphate groups attach to the receptor inside the cell and regulate receptor sensitivity (via phosphorylation) to agents such as alcohol

20. GABAergic Drugs • Agonists (anti-anxiety) • Benzodiazepines • Barbiturates • Ethyl alcohol (ETOH) • Antagonists • Picrotoxin • Inverse agonist • Ro 15-4513 Ro15-4513, a GABAa antagonist (indirect for GABA, direct for alcohol) reverses alcohol intoxication

21. Biogenic Amines • Medium concentration in brain (nanomolar) • Circuits • Single-source divergent projections • Mainly midbrain to cortex • Modulatory functions • Excitatory or inhibitory as a function of receptor • More metabotropic receptors than ionotropic, but plenty of both • Slow acting, long duration (10-1000 ms) • Examples: Acetylcholine, Epinephrine, Norepinephrine, Dopamine, Serotonin

22. Acetyl CoA + Choline CoA + ACh Choline Acetyltransferase (ChAT) Acetate + Choline Ach Acetylcholine Esterase (AChE) Acetylcholine • Mostly excitatory effects Removal Synthesis • 2 receptor types • Nicotinic (ionotropic) • Muscarinic (metabotropic)

23. Major ACh Pathways • Dorsolateral Pons  mid/hindbrain [REM sleep] • Basal Forebrain  cortex [Learning (esp. perceptual), Attention] • Medial Septum  Hippocampus [Memory]

25. Catecholamines Dopamine - DA Dopaminergic Norepinephrine - NE Noradrenergic Epinephrine - E Adrenergic ~ Indolamines Serotonin - 5-HT Serotonergic Monoamines

26. Monoamines (DA, NE, 5-HT) • Modulatory (can have both excitatory and inhibitory effects- varies by receptor) • Recycled by reuptake transporter • Excess NT in terminal broken down by • monoamine oxidase (MAOA/B) • catechol-O-methyltranferase - COMT • Axonal varicosities (bead-like swellings) with both targeted and diffuse release

27. Tyrosine L-DOPA DA Tyrosine Hydroxylase DOPA Decarboxylase Dopamine • Rewarding/motivating effects • Biosynthesis: • Dopamine reuptake transporter (DAT) • 5 receptor types (D1–D5, all metabotropic) • D1 (postsynaptic) • D2 (pre autoreceptors and postsynaptic) • Autoreceptors are release-regulating homeostatic mechanisms

28. Major DA Pathways • Nigrostriatral (Substantia Nigra  Striatum) [Motor movement] • Mesolimbic (VTA  limbic system) [Reinforcement and Addiction] • Mesocortical (VTA  prefrontal cortex) [Working memory and planning] • Tuberoinfundibular tract (hypothalamus  pituitary) [neuroendocrine regulation]

29. DA NE Dopamine Beta-hydroxylase Norepinephrine • Generally excitatory behavioral effects • Biosynthesis: • Many receptor types (metabotropic) • 1, 1-2 (postsynaptic, excitatory) • 2 (autoreceptor, inhibitory)

30. Major NE Pathway • Locus Coeruleus  throughout brain [vigilance and attentiveness]

31. Tryptophan 5-HTP 5-HT Tryptophan Hydroxylase 5-HT Decarboxylase Serotonin • Varying excitatory and inhibitory behavioral effects • Biosynthesis: • At least 14 receptor types, all metabotropic and postsynaptic except: • 5-HT1A,B,D (autoreceptors) – found in CNS • 5-HT3(inhibitory, ionotropic) – found in the intestines

32. Major 5-HT Pathways • Dorsal Raphe Nuclei  cortex, striatum • Medial Raphe Nuclei  cortex, hippocampus • Roles in: • Mood • Eating • Sleep and dreaming • Arousal • Pain • Aggression

34. Indirect Monoamine Agonists • MAOIs Iproniazid • Reuptake blockers • Tricyclic antidepressants • Imipramine • Desipramine - SSRIs • Cocaine & Amphetamine ~

35. Neuropeptides • Low concentration in brain (picomolar) • Large vesicles • Co-localized with other transmitters • Circuits • Interneuronal • Modulatory functions • Mostly inhibitory • Virtually all metabotropic • Slow acting, long duration (10-1000 ms) • Examples: Enkephalins, Endorphins, Oxytocin, Vasopressin, Opioids

36. Opioids • -endorphin • made from proopiomelanocortin (POMC) • produced in pituitary gland, hypothalamus, brain stem • Enkephalin • made from proenkephalin (PENK) • produced throughout brain and spinal cord • Dynorphin • made from prodynorphin (PDYN) • produced throughout brain and spinal cord

37. Opioids Receptors Receptor High affinity ligands mu-endorphin, enkephalins delta enkephalins kappa dynorphins • Opioids act at all opioid receptors, but with different affinities • Distributed throughout brain and spinal cord, especially in limbic areas • Some overlap but quite distinct localizations

38. Opioid Receptors (cont.) • Metabotropic, with either • moderately fast indirect action on ion channels • long-term action via changes in gene expression • Most analgesic effects from mu receptor action • Some analgesic effects from delta • Many negative side effects from kappa

39. Endorphins • Morphine and heroin are agonists that bind to receptor sites, thereby increasing endorphin activity

40. An Evolutionary PerspectiveNesse and Berridge, 1997 “The problem is rooted in the fundamental design of the human nervous system” • An electrochemical brain • Neurotransmitters have retained function for millions of years and are found in many species - from invertebrates to humans • Maximization of Darwinian fitness • Evolution created many chemically-mediated adaptive and self-regulatory mechanisms to control emotion and behavior • Mismatch between ancient chemical mechanisms and modern environments

41. Darwinian Fitness • DA and opioids are part of chemically-mediated incentive mechanisms that act as signals (motivation/reward) for a fitness benefit • you “like” something (opioids) or • you “want” something (dopamine) • Furthermore, DA plays a role in drawing attention/highlighting significant or surprising stimuli • Mechanisms for greater control? As a means to prioritize likes? for anticipatory processing? facilitates learning? • These functions become susceptible to disruption and addiction from external chemical signals

42. Mismatch • Technological inventions such as the hypodermic needle, synthetic psychoactive drugs, video games, snacks etc are evolutionarily novel features that create specific ecological pressures • They can be inherently pathogenic because they bypass the adaptive mechanisms and act directly on neurotransmitter systems • positive emotions are signals to approach • drugs that artificially induce positive emotions give a false signal of a fitness benefit • under some circumstances this could be beneficial (increase empathy) • negative emotions are signals to avoid • drugs that block negative emotions can impair useful defenses • is there utility to anxiety? jealousy? low mood and depression (decrease the tendency for behaviors that are dangerous or useless? embarrassment and guilt (regulating the individual’s hierarchical role in a group?

43. Drug Effects • External drugs hijack these evolved incentive mechanisms and most likely impair adaptation • When exposed to drugs the wanting system motivates persistent pursuit of drugs that no longer give pleasure – a core feature of addiction. • Drugs produce sensitization of incentive mechanisms